We report a case of dermatomyositis associated with molecular evidence of parvovirus B19 DNA in two muscle biopsies collected 5 months apart. IgG-but not IgM-specific antibodies were detected in serum. None of four serum samples was positive for parvovirus B19 DNA. The two biopsies contained B19 VP1 sequences and the second one was also positive for NS1. This is the first report of viral parvovirus B19 DNA in muscle of a patient with dermatomyositis. Latent muscle infection may contribute to the clinical picture.
Dermatomyositis (DM ) is a rare muscle disorder classiand Jo1 were negative. HLA genotype was A2-A4-B45-B50-DR4B1*0406-DR7-DR53-DQ2-DQ4. fied as an autoimmune disease [1] . However, the acute onset of myositis as a viral-like syndrome in some An EMG-guided deltoid muscle biopsy was performed 10 weeks after the onset of symptoms. It showed perivaspatients is one of the reasons for suspecting the involvement of infectious agents in various systemic connective cular lymphocyte and plasmocyte infiltration with areas of muscular necrosis. A diagnosis of DM was considtissue diseases. In particular, parvovirus B19 has been demonstrated in the synovium of patients with rheumaered. No family history of neuromuscular and autoimmune diseases was found. The patient was not exposed toid arthritis [2] . We report here a case of DM associated with the presence of parvovirus B19 DNA in muscle to chemicals or particular drugs before or during the onset of disease. No recent history of infection, in biopsy. particular with parvovirus B19, was found in the family. In February 1997, treatment with prednisone Case report (20 mg/day) and i.m. methotrexate (MTX ) (12.5 mg/week) was started. The clinical outcome was A 48-yr-old woman, without previous medical history, suffered from polyarthralgia in 1995 for 4 months. good and 3 months later the patient did not complain of any pain but had some proximal lower limb muscle Recurrence of these complaints, associated with fatigue, an urticarian rash, muscle pain and weakness, started weakness. A biopsy of the right quadriceps femoris muscle was performed in June 1997. In this biopsy, the in December 1996, without pulmonary or gastrointestinal manifestations or hepatitis. Because of the persistinitial lesions were less severe. In June 1997, serum creatinine phosphokinase was normal but aldolase was ence of these symptoms, the patient was hospitalized in February 1997. Joint examination showed painful 9 IU/l. However, doses of prednisone and MTX were decreased gradually from June to September 1997 withsecond and third metacarpophalangeal joints and feet, without evidence of swelling. There was significant out relapse. The patient was maintained on MTX alone for a total of 2 yr and has been disease-free since MTX muscle weakness associated with a purple rash of the upper eyelids. An electromyographic study showed a was stopped.
Because of the association of arthralgia and a rash, myogenic pattern. The erythrocyte sedimentation rate was 100 mm but C-reactive protein was normal. Serum serum and muscle biopsies were analysed for the presence of parvovirus B19 antibodies and DNA. creatinine phosphokinase was 724 IU/l (normal value 30-125) and aldolase 22 IU/l (normal value <7.6).
Serological analysis of parvovirus B19 antibodies was performed on four sequential serum samples (4 January, Tests for rheumatoid factor and antinuclear antibodies were positive [1/7016 ( latex assay) and 1/4096, 24 February, 17 June and 9 September 1997), using different commercial kits for enzyme immunoassay respectively]. Antibodies SSA, SSB, Sm, RNP, Scl70 ( EIA). The presence of specific IgG was tested with a synthetic peptide derived from two capsid proteins, viral (Parvovirus B19 IgM EIA; Biotrin, Dublin, Ireland ) parvovirus B19 DNA. Conversely, the two muscle biopsies (27 February and 17 June) contained parvovirus B19 was used for detection of specific IgM. Serological analysis for other viruses [coxsackie virus, echo virus, VP1 sequences ( Fig. 1) . The second one was also positive for NS1. Parvovirus B19 DNA was not detected in influenza virus, adenovirus, human immunodeficiency virus ( HIV ), human T-cell leukaemia-lymphoma virus muscle biopsies of three control individuals. Parvovirus B19 is a single-stranded DNA virus that type I ( HTLV-1)] were performed on the same samples.
Detection of parvovirus B19 DNA in the four serum causes erythema infectiosum, arthralgia, aplastic crisis (particularly in patients with red cell defects) and chronic samples and two muscle biopsies from the patient was performed after amplification by the polymerase chain anaemia in immunocompromised patients [6 ] . More recently, parvovirus B19 has been associated with autoreaction (PCR). Vastus lateralis muscle biopsies of three patients undergoing hip replacement for osteoarthritis immune connective tissue diseases [7] . In particular, a large proportion of rheumatoid arthritis synovial were used as controls. Briefly, muscle biopsies were mechanically disrupted in RBS buffer (10 m Tris-HCl, biopsies was found to contain parvovirus B19 DNA [2] but the significance of this remains controversial [8] . pH 7.4, with 10 m NaCl and 25 m EDTA) then digested by proteinase K (1 mg/ml in sodium dodecyl Regarding muscle diseases, several cases of myositis sulphate 10%; Sigma, St Louis, MO, USA) at 37°C overnight. After phenol extraction and ethanol precipitation, air-dried DNA pellets were resuspended in 0.1  Tris-EDTA. The same procedure was applied to two parvovirus B19-positive sera used as a positive PCR control and a negative control (200 ml H 2 O instead of serum). Serum samples were treated with proteinase K. Serum samples (200 ml ) were mixed with 100 ml 10 × lysis buffer (10 m Tris-HCl, pH 8.3, 50 m KCl, 2.5 m MgCl 2 and 0.45% Tween 20) and 100 mg/ml proteinase K, then incubated at 56°C for 1 h, then at 95°C for 10 min. The total volume of PCR mixture was 100 ml, and included either 1 or 10 ml of muscle and either 0.1 or 1 ml of serum DNA extracts.
Two sets of primers were selected to amplify two genomic sequences, the first coding for VP1 and the second for non-structural protein 1 (NS1). Primers A (5∞ GTG CTT ACG TGT CTG GAT TGC 3∞, sense nucleotides 2408-2422) and B (5∞ GCT AAC TTG CCC AGG CTT GT 3∞, antisense nucleotides 2809-2790) amplified (34 cycles at an annealing temperature of 48°C ) a 402-base pair (bp) fragment located within the VP1 coding sequence [3] . Amplified products were detected by ethidium bromide staining after agarose gel electrophoresis. Specific identification was performed with a biotin-labelled probe (5∞ AAT ATT AAA AGA  TCA TTA TAA TAT TTC TTT AGA TAA TCC CC  3∞, nucleotides 
HTLV-1).
with the first biopsy were identical except for the NS1 products, which were not seen.
None of the four serum samples was positive for with the possible involvement of parvovirus B19 have This is the first report of viral parvovirus B19 DNA been described. In two patients with a clinical picture in muscle of a patient with all the classical features of highly suggestive of systemic lupus erythematosus, DM. The demonstration of a direct link will need a increased creatinine phosphokinase and aldolase levels prospective study with large numbers of patients with were associated with acute parvovirus B19 infection, as such a rare disease. indicated by elevated IgM and IgG antibodies, but no viral examination was done in the muscle biopsy [9] .
